- Home
- CLMT vs VRDN Comparison
CLMT vs VRDN Comparison
Compare CLMT & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLMT
- VRDN
- Stock Information
- Founded
- CLMT 1916
- VRDN 2006
- Country
- CLMT United States
- VRDN United States
- Employees
- CLMT N/A
- VRDN N/A
- Industry
- CLMT Oil & Gas Production
- VRDN Medical Specialities
- Sector
- CLMT Energy
- VRDN Health Care
- Exchange
- CLMT Nasdaq
- VRDN Nasdaq
- Market Cap
- CLMT 1.4B
- VRDN 1.6B
- IPO Year
- CLMT 2006
- VRDN N/A
- Fundamental
- Price
- CLMT $14.93
- VRDN $16.27
- Analyst Decision
- CLMT Buy
- VRDN Buy
- Analyst Count
- CLMT 5
- VRDN 12
- Target Price
- CLMT $23.60
- VRDN $36.44
- AVG Volume (30 Days)
- CLMT 1.4M
- VRDN 941.3K
- Earning Date
- CLMT 02-28-2025
- VRDN 03-04-2025
- Dividend Yield
- CLMT N/A
- VRDN N/A
- EPS Growth
- CLMT N/A
- VRDN N/A
- EPS
- CLMT N/A
- VRDN N/A
- Revenue
- CLMT $4,216,399,999.00
- VRDN $302,000.00
- Revenue This Year
- CLMT N/A
- VRDN $3.30
- Revenue Next Year
- CLMT $1.56
- VRDN N/A
- P/E Ratio
- CLMT N/A
- VRDN N/A
- Revenue Growth
- CLMT 0.30
- VRDN N/A
- 52 Week Low
- CLMT $9.97
- VRDN $11.40
- 52 Week High
- CLMT $25.29
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- CLMT 35.94
- VRDN 36.43
- Support Level
- CLMT $15.40
- VRDN $15.62
- Resistance Level
- CLMT $19.14
- VRDN $18.15
- Average True Range (ATR)
- CLMT 1.16
- VRDN 0.91
- MACD
- CLMT -0.01
- VRDN -0.20
- Stochastic Oscillator
- CLMT 9.66
- VRDN 14.48
About CLMT Calumet Specialty Products Partners L.P. Common Units
Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.